Aktiechat - investeringstips

	13/5 15:29 af Helge Larsen/PI-redaktør	This session is over.
	13/5 15:29 af Jan Van de Winkel	Thank you very much. We look forward to ASCO as well as the next ProInvestor QA next quarter.
	13/5 15:28 af Helge Larsen/PI-redaktør	Jan..Thank You for joining us and thank you for the many fulfilling answers to our questions. We wish you a very good presentation at ASCO. We look forward to to seeing you back here on ProInvestor in the near future.
	13/5 15:27 af Jan Van de Winkel	We have had some good coverage for example in the Netherlands (in the key financial press) in April, and we get regular coverage of our newsflow internationally.
	13/5 15:26 af Helge Larsen/PI-redaktør	We noticed the good publicity Genmab get in Denmark. How does it look abroad? :-)
	13/5 15:26 af Jan Van de Winkel	There is no other company that we are aware of that has the capability to create over a 1000 bispecific molecules each day.
	13/5 15:25 af Jan Van de Winkel	The two key ones for our own pipeline are daratumumab subcue formulation potentially this year, and HuMax-AXL-ADC, which is expected in 2016
	13/5 15:24 af Solsen	Mr. Winkel Are you aware of any other co. that can create that amount of antibodies in such a short time as you can - was it 1300 pr day you told us yesterday ?
	13/5 15:24 af Jan Van de Winkel	This year we have multiple IND filings in our milestones. The first one was for HuMax-TAC-ADC (with ADC Therapeutics), we expect several more to come.
	13/5 15:23 af Solsen	Mr Winkel Do you have any information to us about any IND this year (t imeline). And can we expect some fra Genmabs "own" pipeline ?
	13/5 15:22 af Jan Van de Winkel	The focus on daratumumab is the monotherapy Phase 2 study in double refractory multiple myeloma, the focus for ofatumumab will be on the Idealisib Phase 3 combination study run by Gilead.
	13/5 15:21 af Henrik Munthe-Brun	Can you tell something about what we expect will be presented around DARA and Arzerra at ASCO ?
	13/5 15:20 af Jan Van de Winkel	You will need to wait for further news on HuMax-TF-ADC, if data warrants expansion of the program, we are now in a position to fund studies within this program.
	13/5 15:19 af Solsen	Mr. Winkel Do you expect new ph2 with Humax TF-ADC this year or will you only expand the ph1 ?
	13/5 15:18 af Jan Van de Winkel	The initial submission will contain data from at least 4 studies with daratumumab and the actual label will be decided by the regulators.
	13/5 15:17 af Jan Van de Winkel	You can expect four abstracts on dara data and a HuMax-TF-ADC abstract, one on HuMax-AXL-ADC and an abstract from Gilead on ofatumumab plus Idealisib. As communicated yesterday the abstract on the Phase 2 daratumumab monotherapy study will be released on May 30th and not tonight.
	13/5 15:16 af Helge Larsen/PI-redaktør	What is the possibilites for at get a broader label for daratumumab in the upcoming fillings?
	13/5 15:16 af Jan Van de Winkel	We are thrilled to get a presentation spot at ASCO for this early clinical data.
	13/5 15:16 af Henrik Munthe-Brun	What can we expect to night regarding the abstracts ?
	13/5 15:15 af Jan Van de Winkel	This is not a Janssen sponsored study, but a research study by Professor Plesner's team, as there are several other research studies. The precise details are to be released by the Principal Investigators.
	13/5 15:15 af investor1989	Humax-TF-ADC did only get a poster presention instead of an oral presentation at ASCO. It was a Little disappointing to some of us. ?
	13/5 15:14 af Jan Van de Winkel	Later today we expect to see the ASCO abstracts released, the abstract for HuMax-TF-ADC was written in December and the actual presentation will therefore have updated data up to the end of May.
	13/5 15:13 af Solsen	Mr. Winkel Do you use other chemo or checkpoints in the trial with Plesner in Vejle (dara+len+dex) to control or manipulate T- regs - as I belive is the purpose with the trial (references). Or Iam completely wrong ?
	13/5 15:13 af Jan Van de Winkel	As we have started in the past years, we will provide information on programs close to entering the clinic in the coming time.

	13/5 15:12 af Solsen	Dear Mr Winkel. We are very excited about the newsflow over the coming month. Is the data on ASCO from humax TF ADC from full dose or do we have to wait longer for the first full dose results - do you have reached DTL ?
	13/5 15:12 af Jan Van de Winkel	The Novartis programs are effectively proceeding, we have given no further guidance on the exact milestones.
	13/5 15:11 af investor1989	Is it still you thougth that we will hear more about whats in the 20 preclinic programs Genmab currently have. You say it is the strongest preclinical pipeline you have ever had, so it would be great if we can get to see more from it
	13/5 15:11 af Jan Van de Winkel	This is a Gilead study, starting during the GSK era. We very much look forward to seeing the data and the ASCO abstract, later today.
	13/5 15:11 af Sukkeralf	Jan in yesterdays CC you mentioned that we probably will here more about the Novartis DuoBody collaboration - milestone due to progress or actual targets you´re aiming at ?
	13/5 15:10 af Jan Van de Winkel	GSK confirmed the wording in our 2015 Q1 report.
	13/5 15:10 af Sukkeralf	Do Genmab/Novartis have any contact with Gilead regarding the Idelalisib/Ofatumumab clinical trial in CLL - and if data is good enough for filing do you then take part in this ?
	13/5 15:09 af Jan Van de Winkel	then it is down to planning novel studies with new combinations of drugs and we are thrilled to have a good new partner in Novartis.
	13/5 15:09 af Sukkeralf	When was the last time you got a confirmation from GSK about start of autoimmune clinical trials (NCO/RRMS) with Ofatumumab ?
	13/5 15:09 af Jan Van de Winkel	The next concrete steps are to file for a broader label based on excellent data in two phase 3 studies - one in the maintenance setting and one in the relapsed CLL setting in 2015...
	13/5 15:07 af Sukkeralf	Jan which specific Ofatumumab clinical trial combinations do you think could put Arzerra on the map in the comming years?
	13/5 15:06 af Jan Van de Winkel	the current research program with Lilly was completed, and Lilly were very impressed with the platform, but did not have a suitable project for a bispecific approach at this time.
	13/5 15:05 af investor1989	You "completed" the Eli Lilly Duobody partnership" is it terminated or what is next step - a license deal ?
	13/5 15:05 af Jan Van de Winkel	We have not given a timetable on the new immuno oncology product candidates yet, but there are some very exciting combinations and work is already underway.
	13/5 15:04 af investor1989	The BioNovion collaboration. Is 2017 the time of the first IND here or can it be 2016 if you speed up or what is to expect from that.
	13/5 15:04 af Helge Larsen/PI-redaktør	Ok. Thank You.
	13/5 15:03 af Jan Van de Winkel	the finances, we reiterated guidance for the full year 2015 and ended the quarter with nearly 3bn DKK in cash.
	13/5 15:03 af Jan Van de Winkel	and signed a new deal with BioNovion and acquired a key asset from iDD, a French biotech company...
	13/5 15:02 af Jan Van de Winkel	and hitting the primary endpoint in the Ofatumumab Phase 3 in relapsed CLL in April...
	13/5 15:01 af Jan Van de Winkel	Yes we would be delighted....we improved the operating result, but maybe even more important was the positive topline Phase 2 data with daratumumab....
	13/5 15:00 af Helge Larsen/PI-redaktør	Let's start. Can you give a short-term update on key figures and important events in the first quarter?
	13/5 14:59 af Jan Van de Winkel	We are ready. I will be joined by David Eatwell, Genmab's CFO too.
	13/5 14:59 af Helge Larsen/PI-redaktør	Welcome to the Q & A here on the ProInvestor, Jan van de Winkel. We are very happy that you are back in here and ready to answer questions from our investors.
	13/5 14:58 af Jan Van de Winkel	Yes I am here. Nice to be with you again. We are ready to start in a couple of minutes.
	13/5 14:57 af Helge Larsen/PI-redaktør	Are you with us here online, Jan?
	13/5 14:54 af Helge Larsen/PI-redaktør	In 5 minutes we begin the online Q & A with Genmab.